Keyphrases
Bacteremia
14%
CA-MRSA
21%
Children's Hospital
16%
Consensus Statement
17%
Core Genome multilocus Sequence Typing (cgMLST)
17%
COVID-19
100%
COVID-19 in children
14%
COVID-19 Management
14%
COVID-19 Pandemic
18%
COVID-19 Prevention
19%
COVID-19 Treatment
14%
Critically Ill children
17%
Expert Opinion
39%
In-person Education
14%
Infection Prevention
21%
Infection Treatment
14%
Infections in children
14%
Interim Guidance
14%
Introduction Event
14%
Methicillin-resistant Staphylococcus Aureus
14%
Meticillin-resistant S. Aureus
14%
Missouri
31%
Mitigation Strategies
18%
Odds Ratio
14%
Panton-Valentine Leukocidin
33%
Pediatric Infectious Disease
50%
Pediatric Transplantation
29%
Prevention Practices
14%
Prospective Cohort Study
17%
Quarantine Policy
14%
Repeat-primed PCR
17%
Returns to Schooling
29%
Risk Factors
20%
School-based
17%
Secondary Transmission
14%
Serotype 6
14%
Severe Disease
26%
Skin Tissue
34%
Soft Tissue Infection
34%
Solid Organ Transplant Recipients
29%
Springfield
14%
St. Louis
33%
Staphylococcal Infections
17%
Staphylococcus Aureus
31%
Teleconferencing
14%
Therapeutic Monoclonal Antibody
29%
Transmission Events
19%
Treatment Practices
14%
United States
29%
Web-based Survey
14%
Medicine and Dentistry
Adolescence
43%
Anaphylaxis
5%
Antiviral Drug
7%
Antiviral Therapy
10%
Artificial Respiration
5%
Bloodstream Infection
14%
Cat-Scratch Disease
14%
Cervical Spine
14%
Chlorhexidine
14%
Chlorhexidine Gluconate
12%
Clinical Trial
6%
Clinician
13%
COVID-19
95%
COVID-19 Therapy
14%
COVID-19 Vaccination
14%
Critical Illness
6%
Debridement
9%
Decision Making
13%
Diseases
23%
Extracorporeal Membrane Oxygenation
5%
Health System
5%
High Risk Population
5%
Hydroxychloroquine
6%
Infection
25%
Infection Control
9%
Infectious Disease
9%
Infectious Disease Treatment
14%
Infusion
5%
Intensive Care
7%
Intensive Care Medicine
8%
Monoclonal Antibody Therapy
29%
Orbital Cellulitis
14%
Osteomyelitis
14%
Panton Valentine Leukocidin
14%
Patient with Cystic Fibrosis
14%
Pediatric Infection
52%
Pediatrics
63%
Pediatrics Patient
10%
Posaconazole
14%
Post-Exposure Prophylaxis
5%
Remdesivir
19%
Risk Stratification
7%
Severe Acute Respiratory Syndrome Coronavirus 2
40%
Soft Tissue Infection
19%
Staphylococcus Aureus
14%
Supportive Care
6%
Transplantation
29%
Virus
5%